Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $216.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $216.1 million; the TTM figure through Mar 2026 stood at $216.1 million (changed N/A YoY), while the FY2025 annual figure was $208.1 million, up 36.52% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $216.1 million, up from $208.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $216.1 million in Q1 2026, with the low at $31.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $66.8 million (2023), against an average of $95.2 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 224.45% in 2022, then advanced 18.81% in 2023.
• Tarsus Pharmaceuticals' Total Non-Current Liabilities stood at $34.9 million in 2022, then surged by 91.48% to $66.8 million in 2023, then surged by 128.38% to $152.5 million in 2024, then surged by 36.52% to $208.1 million in 2025, then grew by 3.83% to $216.1 million in 2026.
• Business Quant data shows TARS's Total Non-Current Liabilities at $216.1 million in Q1 2026, $208.1 million in Q4 2025, and $189.3 million in Q3 2025.